
Crossover in cancer drug trials sparks debate! In a randomized trial, patients in the control arm can receive the experimental agent upon disease progression. ASCO Annual Meeting highlighted various trials with crossover designs, raising concerns. Oncology experts remain divided on the significance of such crossovers, stressing their context dependence. Examples from ASCO 2023 shed light on the matter, exploring the pros and cons of incorporating crossovers in clinical trials.
Like
Save
Share